The comprehensive clinical management of both solid tumors and hematologic cancers is continuously evolving, with new research introducing the utility of novel systemic and supportive therapeutic agents maturing almost daily.
Breast and lung cancer, in isolation, comprise a significant proportion of routine oncology practice and are thus of particular relevance to ongoing education targeting the cross-functional treatment team. Although breast cancer may have a protracted natural history relative to tumors of the lung, both diseases are currently managed with a diverse array of antineoplastic agents, including cytotoxic chemotherapy and molecular-targeted or biologic agents, each with unique side effects and toxicities. In the case of breast cancer, hormonal therapy adds yet another layer of clinical management complexity that oncology care providers must be prepared to successfully address.
In the hematologic cancer space, the non-Hodgkin’s lymphomas (NHL), including chronic lymphocytic leukemia (CLL), and multiple myeloma (MM) are among the most prevalent diseases, and both have been the focus of recent clinical knowledge acquisition and resulting incremental treatment advances. This substantial progress necessitates learning opportunities to ensure that best-practice interventional and supportive management strategies are employed.
The integral role of oncology nurses in the communication and delivery of cancer care spans the psychosocial, supportive and therapeutic management spectra. These pivotal practitioners must be well versed in the evidence to effectively counsel their patients about treatment benefit, risk and impact on quality of life. This activity features group discussion with leading oncology nurses and medical oncologists reviewing the latest research developments in context with practical case application.
To provide the perspectives of oncology nurses and medical oncologists regarding evidence-based treatment recommendations, rational supportive care algorithms and a review of the newest research developments affecting the care of patients with NHL/CLL, MM, breast cancer and lung cancer.
This educational activity for 4.8 contact hours is provided by Research To Practice during the period of October 2010 through October 2011.
Research To Practice is an approved provider of continuing nursing education by the NJSNA, an accredited approver, by the American Nurses Credentialing Center’s Commission on Accreditation.
HOW TO USE THIS CNE ACTIVITY
This is an audio CNE program. This website contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Educational Assessment and Credit Form, as well as links to relevant abstracts and full-text articles.
To receive credit, participants should read the learning objectives and faculty disclosures, listen to the audio MP3s and complete the Post-test and Educational Assessment and Credit Form located at CME.ResearchToPractice.com. A statement of CNE credit will be issued only upon completion of the Post-test, with a score of 75 percent or better, and the Educational Assessment and Credit Form. Your statement of credit will be mailed to you within three weeks or may be printed online.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Ms McKenney had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Czuczman — Advisory Committee: Amgen Inc, Biogen Idec, Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation; Lectures: Biogen Idec, Genentech BioOncology. Ms Downs — Advisory Committee: GlaxoSmithKline; Speakers Bureau: Cephalon Inc, Genentech BioOncology, Millennium Pharmaceuticals Inc. Ms Goodrich — Advisory Committee: Cephalon Inc. Dr Gregory — Advisory Committee: Cephalon Inc; Consulting Agreements: Amgen Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Spectrum Pharmaceuticals Inc; Speakers Bureau: Cephalon Inc, Genentech BioOncology. Ms Faiman — Advisory Committee: Celgene Corporation, Millennium Pharmaceuticals Inc; Speakers Bureau: Celgene Corporation, Medtronic Inc, Millennium Pharmaceuticals Inc. Dr Ghobrial — Advisory Committee: Celgene Corporation, Novartis Pharmaceuticals Corporation; Speakers Bureau: Celgene Corporation, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation. Dr Lonial — Advisory Committee, Consulting Agreements and Paid Research: Bristol-Myers Squibb Company, Celgene Corporation, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation. Ms Richards — Advisory Committee: Millennium Pharmaceuticals Inc; Speakers Bureau: Celgene Corporation, Millennium Pharmaceuticals Inc. Ms Major Campos — Advisory Committee: Pfizer Inc; Speakers Bureau: Genentech BioOncology, Genomic Health Inc. Dr Rugo — Speakers Bureau: AstraZeneca Pharmaceuticals LP. Dr Swain — Paid Research: Bristol-Myers Squibb Company, Genentech BioOncology; Paid Travel: Sanofi-Aventis. Ms Culkin — Advisory Committee and Speakers Bureau: Genentech BioOncology, Lilly USA LLC; Consulting Agreement: Lilly USA LLC. Dr DiSalvo — Advisory Committee and Speakers Bureau: Genentech BioOncology; Speakers Bureau: Sanofi-Aventis. Dr Lara — Consulting Agreements: Eisai Inc, Genentech BioOncology, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc; Paid Research: Bayer HealthCare Pharmaceuticals, Exelixis Inc, GlaxoSmithKline, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi-Aventis; Speakers Bureau: Genentech BioOncology, Pfizer Inc. Dr Riely — Advisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc.
EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: Abraxis BioScience, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, Lilly USA LLC, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff, planners, managers and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This program is supported by educational grants from Abraxis BioScience, Biogen Idec, Cephalon Inc, Genentech BioOncology, Millennium Pharmaceuticals Inc and OSI Oncology.
Hardware/Software Requirements:
An Internet connection that is at least 28.8 Kbps
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
Macromedia Flash plug-in 6.0 or greater
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: October 2010
Expiration date: October 2011
